Elkhorn Partners Limited Partnership Acquires Shares of 1,000 CRISPR Therapeutics AG (NASDAQ:CRSP)

Elkhorn Partners Limited Partnership acquired a new stake in CRISPR Therapeutics AG (NASDAQ:CRSP) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 1,000 shares of the company’s stock, valued at approximately $54,000.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Global Trust Asset Management LLC raised its holdings in shares of CRISPR Therapeutics by 150.0% during the 2nd quarter. Global Trust Asset Management LLC now owns 500 shares of the company’s stock worth $27,000 after acquiring an additional 300 shares during the period. Larson Financial Group LLC raised its holdings in shares of CRISPR Therapeutics by 95.5% during the 2nd quarter. Larson Financial Group LLC now owns 565 shares of the company’s stock worth $31,000 after acquiring an additional 276 shares during the period. GPS Wealth Strategies Group LLC raised its holdings in shares of CRISPR Therapeutics by 99.7% during the 2nd quarter. GPS Wealth Strategies Group LLC now owns 615 shares of the company’s stock worth $33,000 after acquiring an additional 307 shares during the period. Riggs Asset Managment Co. Inc. raised its holdings in shares of CRISPR Therapeutics by 66.7% during the 1st quarter. Riggs Asset Managment Co. Inc. now owns 500 shares of the company’s stock worth $34,000 after acquiring an additional 200 shares during the period. Finally, Principal Securities Inc. purchased a new position in shares of CRISPR Therapeutics during the 4th quarter worth $41,000. Hedge funds and other institutional investors own 69.20% of the company’s stock.

Insider Buying and Selling

In related news, COO Julianne Bruno sold 3,366 shares of the business’s stock in a transaction dated Friday, June 21st. The shares were sold at an average price of $56.09, for a total transaction of $188,798.94. Following the sale, the chief operating officer now owns 6,745 shares of the company’s stock, valued at $378,327.05. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 4.10% of the stock is owned by insiders.

Analyst Ratings Changes

Several research analysts have recently commented on CRSP shares. Chardan Capital reduced their price target on CRISPR Therapeutics from $112.00 to $94.00 and set a “buy” rating on the stock in a report on Tuesday, August 6th. Truist Financial lowered their price objective on shares of CRISPR Therapeutics from $120.00 to $100.00 and set a “buy” rating for the company in a research report on Monday, August 12th. Barclays lowered their price objective on shares of CRISPR Therapeutics from $67.00 to $59.00 and set an “equal weight” rating for the company in a research report on Tuesday, August 6th. Citigroup lowered their price objective on shares of CRISPR Therapeutics from $89.00 to $84.00 and set a “buy” rating for the company in a research report on Thursday, May 23rd. Finally, Guggenheim reaffirmed a “neutral” rating on shares of CRISPR Therapeutics in a research report on Friday, June 28th. Three research analysts have rated the stock with a sell rating, eight have assigned a hold rating and nine have issued a buy rating to the stock. According to data from MarketBeat, CRISPR Therapeutics currently has a consensus rating of “Hold” and a consensus target price of $75.63.

CRISPR Therapeutics Stock Performance

NASDAQ CRSP opened at $49.87 on Wednesday. The firm has a market cap of $4.23 billion, a PE ratio of -18.33 and a beta of 1.68. CRISPR Therapeutics AG has a one year low of $37.55 and a one year high of $91.10. The firm’s fifty day moving average is $50.91 and its two-hundred day moving average is $57.51.

CRISPR Therapeutics (NASDAQ:CRSP) last issued its earnings results on Monday, August 5th. The company reported ($1.49) earnings per share for the quarter, missing the consensus estimate of ($1.43) by ($0.06). The firm had revenue of $0.52 million for the quarter, compared to analyst estimates of $12.31 million. The firm’s quarterly revenue was down 99.3% on a year-over-year basis. During the same quarter last year, the firm posted ($0.98) earnings per share. Research analysts predict that CRISPR Therapeutics AG will post -5.6 earnings per share for the current year.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.